EP22: Portal Vein Thrombosis: Targeting Clotting Risk in Liver Disease

In our 22nd episode, we take a closer look at cirrhotic portal vein thrombosis, a clinically significant vascular condition characterized by the thrombotic occlusion of the portal vein in patients with underlying liver disease. Together, let’s raise awareness and contribute to better patient outcomes!

Werfen is committed to Powering Patient Care by fostering education and raising awareness of thrombotic disorders, with the ultimate aim of improving clinical outcomes. This episode focuses on cirrhotic portal vein thrombosis, a clinically relevant vascular condition characterized by the obstruction of the portal vein by a blood clot in individuals with underlying liver disease.

Introduction

Traditionally, liver disease has been linked to an increased bleeding risk due to reduced production of coagulation factors. However, contemporary understanding recognizes a “rebalanced” hemostatic state, where both procoagulant and anticoagulant pathways are diminished. A common complication of advanced liver disease is portal vein thrombosis (PVT), a partial or complete obstruction of the portal vein caused by thrombus formation, which may extend to the superior mesenteric and splenic veins.

Pathophysiology

Liver dysfunction profoundly alters the hemostatic system. This unstable equilibrium may shift toward thrombosis under additional triggers such as systemic inflammation, endothelial injury, or infection. As cirrhosis progresses, structural and functional changes within the liver increase the intrahepatic vascular resistance, promoting the development of portal hypertension. This hemodynamic alteration reduces portal blood flow, contributing to the increased risk of thrombosis.

Epidemiology

PVT is broadly categorized into the cirrhotic (more frequent) and non-cirrhotic (less common) forms. Its exact incidence in cirrhotic patients remains uncertain, with reported rates ranging from approximately 4.4% to 15.8%. Although uncommon in the general population, PVT becomes significantly more prevalent in advanced liver disease and portal hypertension, affecting approximately 8% to 25% of cases.

Clinical Presentation and Complications

Clinically, PVT patients may be asymptomatic, particularly in early or partial thrombosis. When symptoms occur, they are often nonspecific, including abdominal pain, splenomegaly, or signs of portal hypertension such as ascites and variceal bleeding. In more advanced cases, extension of the thrombus into the mesenteric circulation can lead to intestinal ischemia, a serious and potentially life-threatening complication.

Diagnosis

Standard coagulation tests do not adequately reflect the complex hemostatic balance in these patients, and therefore diagnosis relies primarily on imaging. Doppler ultrasonography is typically the first-line tool, allowing real-time evaluation of portal vein patency and blood flow. Cross-sectional assessment with computed tomography or magnetic resonance imaging is often required to determine the full extent of the thrombosis, identify complications, and evaluate underlying causes.

Management

Treatment approaches include anticoagulants, thrombolytic therapy and transjugular intrahepatic portosystemic shunt, chosen almost on a case-by-case basis depending on the characteristics of the patient and the thrombus. When anticoagulants are selected, the risk–benefit balance must be carefully considered, especially in advanced cirrhosis. LMWH appears more effective than warfarin for complete resolution, while DOACs remain less commonly used.

Conclusion and Outlook

Cirrhotic portal vein thrombosis represents a complex intersection between thrombosis and liver disease. Its pathophysiology highlights the delicate balance of the hemostatic system, while its clinical course can vary widely depending on disease severity and early recognition. Increasing awareness of PVT in this context is essential to improve early detection, guide effective management strategies, and ultimately improve patient care and outcomes.